ArticleBMC cancer2018

Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL.

Takeshi Kashiwabara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.